In this study, we clarified that limonin could alleviate fatty liver disease in vitro and in vivo experiments, including decreased liver lipid accumulation and down-regulated the expression of lipogenic transcription factors FASN and SREBP1, which were up-regulated by de novo lipogenesis and ultimately induce steatosis (Anderson and Borlak, 2008). Here, FASN is linked to fatty liver disease.